Prevention of respiratory syncytial virus infection in infants
- PMID: 15117767
- PMCID: PMC403830
- DOI: 10.1136/bmj.328.7447.1026
Prevention of respiratory syncytial virus infection in infants
Figures
References
-
- The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high risk infants. Pediatrics 1998;102: 531-7. - PubMed
-
- American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, ed. Red Book: 2003 Report of the committee on infectious diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003: 523-8.
-
- Joint Committee on Vaccination and Immunisation. Minutes of the meeting held on 1 November 2002. www.doh.gov.uk/jcvimins01nov02.htm (accessed 4 Mar 2004).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical